ILMN Illumina Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ILMN

Price (delayed)

$226.58

Market cap

$34.26B

P/E Ratio

38.53

Dividend/share

N/A

EPS

$5.88

Enterprise value

$35.2B

?
Relative Growth: Rel. Growth: 42
Relative Strength: Rel. Strength: 93
Relative Valuation: Rel. Valuation: 28
Relative Profitability: Rel. Profitability: 92

The Illumina Billion Cell Atlas — the world's largest genome-wide genetic perturbation dataset — is capturing how one billion individual cells respond to genetic changes via CRISPR across more than ...

Highlights
The quick ratio has soared by 75% YoY and by 47% from the previous quarter
The equity has increased by 32% YoY and by 11% from the previous quarter
The stock's price to earnings (P/E) is 23% more than its last 4 quarters average of 31.2
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.illumina.com
Peers: PACB A TMO DHR

Key stats

What are the main financial stats of ILMN

ILMN stock price

How has the Illumina stock price performed over time
Intraday
-3.99%
1 week
-16.4%
1 month
-17.02%
1 year
83.41%
YTD
72.75%
QTD
-17.21%

Financial performance

How have Illumina's revenue and profit performed over time
Revenue
$4.54B
Gross profit
$3.08B
Operating income
$960M
Net income
$895M
Gross margin
67.9%
Net margin
19.7%
ILMN's net income is up by 27% year-on-year and by 8% since the previous quarter
The operating income has increased by 23% YoY and by 9% from the previous quarter
Illumina's net margin has increased by 20% YoY and by 7% QoQ
Illumina's operating margin has increased by 16% YoY and by 8% from the previous quarter

Price vs fundamentals

How does ILMN's price correlate with its fundamentals

Growth

What is Illumina's growth rate over time

Valuation

What is Illumina stock price valuation
ILMN P/E details
P/E
38.53
P/B
10.88
P/S
7.54
EV/EBIT
30.45
EV/EBITDA
24.56
EV/Sales
7.76
Illumina's EPS has increased by 32% YoY and by 9% QoQ
The stock's price to earnings (P/E) is 23% more than its last 4 quarters average of 31.2
The price to book (P/B) is 67% higher than the 5-year quarterly average of 6.5 and 18% higher than the last 4 quarters average of 9.2
The equity has increased by 32% YoY and by 11% from the previous quarter
ILMN's P/S is 26% above its 5-year quarterly average of 6.0 and 26% above its last 4 quarters average of 6.0
Illumina's revenue has increased by 6% YoY

Efficiency

How efficient is Illumina business performance
The company's return on assets rose by 18% YoY and by 6% QoQ
ILMN's return on invested capital is up by 13% year-on-year
Illumina's return on sales has increased by 10% YoY and by 2.8% QoQ
The ROE has grown by 5% YoY

Dividends

What is ILMN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ILMN.

Financial health

How did Illumina financials performed over time
The total assets is 86% more than the total liabilities
The current ratio has soared by 84% YoY and by 46% from the previous quarter
The quick ratio has soared by 75% YoY and by 47% from the previous quarter
Illumina's debt is 29% lower than its equity
The equity has increased by 32% YoY and by 11% from the previous quarter
The debt to equity is down by 32% year-on-year and by 17% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.